However, advances in the treatment landscape of HER2-positive breast cancer have led to improvements in the cardiac safety profile of current therapies, with greater use of non-anthracycline treatment regimens associated with lower cardiotoxicity. This evidence concerns the gene ERBB2 and breast carcinoma.